Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study assessing Bladder-cancer-therapeutic for non-muscle invasive bladder cancer (NMIBC) patients

Next Previous
Trial Profile

A phase I study assessing Bladder-cancer-therapeutic for non-muscle invasive bladder cancer (NMIBC) patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZH 9 (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms PARADIGM-1

Most Recent Events

  • 02 Nov 2023 According to a Prokarium media release, trial is expected to enroll in H1 2024 across multiple centers in the United States.
  • 02 Nov 2023 According to a Prokarium media release, IND approval validates the innovative design of this trial paving the way for collaboration with top-tier research centers in the U.S.
  • 02 Nov 2023 According to a Prokarium media release, the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for ZH9.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top